FibroBiologics (FBLG) Projected to Post Quarterly Earnings on Thursday

FibroBiologics (NASDAQ:FBLG) is projected to release its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of ($0.93) per share for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:00 PM ET.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($1.33) earnings per share for the quarter, hitting the consensus estimate of ($1.33). On average, analysts expect FibroBiologics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

FibroBiologics Price Performance

Shares of FBLG opened at $0.74 on Thursday. The firm has a market cap of $4.50 million, a P/E ratio of -0.11 and a beta of 1.14. FibroBiologics has a 1 year low of $0.73 and a 1 year high of $14.40. The company has a 50 day simple moving average of $0.92 and a two-hundred day simple moving average of $3.24.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price (up from $4.00) on shares of FibroBiologics in a research note on Thursday, April 16th. D. Boral Capital reiterated a “hold” rating on shares of FibroBiologics in a research note on Thursday, March 26th. Weiss Ratings downgraded shares of FibroBiologics from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday, July 7th. Maxim Group lowered FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Finally, Wall Street Zen upgraded FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $74.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FBLG. AQR Capital Management LLC bought a new stake in FibroBiologics in the first quarter worth $29,000. XTX Topco Ltd raised its stake in FibroBiologics by 160.0% during the second quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock valued at $29,000 after purchasing an additional 28,276 shares in the last quarter. Marshall Wace LLP bought a new position in FibroBiologics during the second quarter valued at $49,000. Cerity Partners LLC lifted its position in FibroBiologics by 37.2% during the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock valued at $80,000 after purchasing an additional 34,702 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of FibroBiologics in the 2nd quarter worth about $60,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.